



## Flamel Technologies Announces Projected Release Date of First Quarter 2013 Results and Conference Call

Lyon, France – April 23, 2013 - Flamel Technologies (NASDAQ: FLML) expects to release certain financial results for the first quarter of 2013, on Tuesday, May 7, 2013, before the market open. A conference call to discuss these results has been scheduled for Tuesday, May 7<sup>th</sup> at 8:30 AM (Eastern Standard Time). A question and answer period will follow management's prepared remarks.

To participate in the conference call, investors are invited to dial 888-428-9473 (U.S. and Canada) or +1-719-325-2315 (international). The conference ID number is 8200950. The conference call webcast may be accessed at [www.flamel.com](http://www.flamel.com).

A replay of the call will be available for 14 days, within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (U.S. and Canada) or +1-719-457-0820 (international), with the passcode 8200950. A replay of the webcast will also be archived on Flamel's website for 90 days following the call.

**About Flamel Technologies.** Flamel Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its partnered pipeline includes biological and chemical drugs formulated with its Medusa<sup>®</sup> and Micropump<sup>®</sup> (and its applications to the development of liquid formulations, i.e. LiquiTime<sup>™</sup> and of abuse-deterrent formulations Trigger Lock<sup>™</sup>) proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company has developed products and manufactures Micropump-based microparticles under FDA-audited GMP guidelines. Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including GlaxoSmithKline (Coreg CR<sup>®</sup>, carvedilol phosphate). The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at [www.flamel.com](http://www.flamel.com).



**Contact: Michael S. Anderson**  
Phone: 33 (0) 4 72 78 34 34  
Fax: 33 (0) 4 72 78 34 35  
E-mail: [anderson@flamel.com](mailto:anderson@flamel.com)

**Investor Relations**

**Bob Yedid**

**ICR Inc.**

Phone: 646-277-1250

Email: [bob.yedid@icrinc.com](mailto:bob.yedid@icrinc.com)

\*\*\*\*\*

*This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that the acquisition of Éclat Pharmaceuticals may not be successfully integrated or that certain payment acceleration events may be triggered; the new hospital-based product under FDA review may not be approved or such approval may be delayed; the reacquisition of the exclusive rights to rights to develop and commercialize IFN-β XL worldwide and identification of an alternative strategic partner for the program may not be successful; the identified opportunities will not result in shorter-term, high value results; clinical trial results may not be positive or our partners may decide not to move forward; management transition may be disruptive or not succeed as planned; products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements; products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities; we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel's technology; and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on Form 20-F for the year ended December 31, 2011 that has been filed with the Securities and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.*